Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Recent HIV-1 Infection
NCT05527418Phase 2Active, not recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in human immunodeficiency virus infection (HIV). Started Jan 2024; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05527418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527418.